BioXcel Therapeutics (BTAI) Tops Q3 EPS by 19c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($0.32), $0.19 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $1.33 million.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Iran Has Resumed Producing Ballistic Missiles, U.S. and Middle East Officials Say - WSJ
• Active options: AAPL NVDA TSLA SPCX MU META INTC ORCL GOOGL AMZN PLTR
• Energy Select Sector SPDR ETF (XLE) call put ratio 1 call to 1.2 puts